METHUSELAH ARCHIVE INTERVENTIONS / SIRTUIN-ACTIVATING COMPOUNDS (RESVERATROL, THEN NMN)

Sirtuin-activating compounds (resveratrol, then NMN)

oral · 2003–present
category:oral
delivery:Oral small-molecule compounds proposed to activate sirtuin enzymes (principally SIRT1) or raise cellular NAD+ levels. The 2003-2013 commercial phase centered on resveratrol and synthetic sirtuin-activating compounds (STACs) developed by Sirtris Pharmaceuticals, including a proprietary micronized resveratrol formulation (SRT501) tested as a prescription drug candidate. The current phase centers on NMN (nicotinamide mononucleotide) and related NAD+ precursors sold as oral dietary supplements (capsules or powder), plus resveratrol itself, which remains separately sold as an over-the-counter supplement.
price tier:premium
era:2003–present
current status:both
regulatory:supplement
SHORT PITCH (AS SOLD)
Small molecules proposed to activate the body's own 'longevity genes' (sirtuins) and mimic the life-extending effects of calorie restriction, discovered in David Sinclair's Harvard laboratory and commercialized first as resveratrol-derived pharmaceuticals, then as NMN and other NAD+-boosting dietary supplements.
THE ACTUAL EVIDENCE
The foundational 2003 finding that resveratrol activates SIRT1 and extends yeast lifespan (Howitz et al., Nature) was mechanistically undermined by 2010: Pfizer researchers (Pacholec et al., Journal of Biological Chemistry) showed the original activation signal was an artifact of the fluorescent assay used to detect it, not a real interaction with unlabeled substrate. A Sirtris-sponsored Phase 2 trial of micronized resveratrol (SRT501) in multiple myeloma patients was terminated in 2010 after 5 of 24 patients developed renal failure (Popat et al., British Journal of Haematology, 2013), and GlaxoSmithKline closed Sirtris's Cambridge, Massachusetts office in 2013, five years after acquiring the company, folding its remaining sirtuin research into GSK's broader R&D operations in Pennsylvania. For the current NMN/NAD+ phase, a May 2026 review by two academic biologists in The Conversation concludes human trials have not shown convincing evidence that NMN, NAD+, or resveratrol slow aging, preserve muscle mass or function in older adults, or improve strength, cognition, frailty, or biological age; the strongest human evidence is limited to short-term changes in blood NAD+-related markers. No randomized controlled trial of any compound in this lineage has demonstrated a lifespan or hard-endpoint benefit in humans.
PRACTITIONERS
INGREDIENTS
CASES
CLAIMS
SOURCES
  1. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan (2003)
  2. SRT1720, SRT2183, SRT1460, and Resveratrol Are Not Direct Activators of SIRT1 (2010)
  3. A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and/or refractory multiple myeloma (2013)
  4. Impairment of an Endothelial NAD+-H2S Signaling Network Is a Reversible Cause of Vascular Aging (2018)
  5. Glaxo Says Compound in Wine May Fight Aging (2008)
  6. GSK moves on Sirtris (2008)
  7. GlaxoSmithKline to close Sirtris unit in Cambridge (2013)
  8. A 'Fountain Of Youth' Pill? Sure, If You're A Mouse. (2019)
  9. Can supplements containing NMN, NAD+ and resveratrol really slow ageing? Here's what the evidence says (2026)
  10. FDA faces new lawsuit from NPA over anti-aging ingredient NMN (2024)
  11. FDA Reverses NMN Decision: Risks, Quality Concerns, & Alternative Options (2025)
  12. Lifespan: Why We Age—and Why We Don't Have To (2019)
  13. Harvard longevity scientist sparks furor with claim about reversing aging in dogs (2024)
  14. After careful consideration, I have renounced my membership in the Academy for Health and Lifespan Research. (2024)
  15. Star Scientist's Claim of 'Reverse Aging' Draws Hail of Criticism (2024)
  16. A 'Reverse Aging' Guru's Trail of Failed Businesses (2024)
  17. Declining NAD+ Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication during Aging (2013)
  18. A Science-Based Review of the World's Best-Selling Book on Aging (2022)
EXTERNAL REFERENCES
NOTES

The intervention has run through two commercial generations built on the same laboratory finding. In 2003, David Sinclair’s team reported that resveratrol, a polyphenol in red wine and grape skin, activated the enzyme SIRT1 and extended yeast lifespan roughly 70% by mimicking calorie restriction. Sinclair co-founded Sirtris Pharmaceuticals in 2004 to develop resveratrol and related “sirtuin-activating compounds” (STACs) as drugs; the company went public in 2007 and GlaxoSmithKline acquired it in 2008 for $720 million, an 84% premium over its trading price (New York Times, 23 April 2008). By 2010, independent researchers at Pfizer showed the core mechanism was an assay artifact, and a Sirtris trial of its lead resveratrol drug candidate was halted after patients developed renal failure; GSK folded the remaining Sirtris research into its Philadelphia operations and closed the Cambridge office in 2013.

The second generation, built around NMN and other NAD+-boosting compounds, began with a December 2013 mouse study from Sinclair’s lab (Gomes et al., Cell) reporting that raising NAD+ with NMN restored old mice’s mitochondrial function to youthful levels in a SIRT1-dependent manner, and continues today through companies Sinclair co-founded or lends his name to, including MetroBiotech (which develops a proprietary NMN formulation, MIB-626, as an investigational drug), a NAD-booster pill Elysium Health sells under a patent licensing him as inventor, and pet supplements sold under his name and credentials. As of 2026, resveratrol and NMN are both sold as over-the-counter dietary supplements in the United States, notwithstanding a 2022-2025 interval in which NMN’s supplement status was contested at the FDA over MetroBiotech’s own investigational-drug filing. No controlled human trial in either generation has demonstrated a lifespan or hard-endpoint anti-aging benefit.